Title: Degree of Dyslipidemia in Patients of Subclinical and Overt Hypothyroidism
Authors: Dr Sankalp Kumar Tripathi MD, Dr M.G. Muddeshwar MSc PhD
DOI: https://dx.doi.org/10.18535/jmscr/v5i1.65
Abstract
Background: Hypothyroidism has been established as a common cause of secondary dyslipidemia. There is also a recognized pathogenic relationship of patients with hypothyroidism developing atherosclerotic cardiovascular disease. This possibility of atherosclerotic cardiovascular disease is attributable to dyslipidemia noticed in hypothyroid states. This study was intended to evaluate the level of different parameters of lipid profile in both subclinical and hypothyroid patients.
Materials and Methods: 104 Hypothyroid patients were divided in two equal groups namely subclinical and overt hypothyroids based on their serum TSH levels. 52 age, sex and weight matched euthyroid controls were used for comparison.
Result: Significantly raised serum total cholesterol, LDL-cholesterol and triglycerides were found in hypothyroid patients and dyslipidemia was more profound in overt hypothyroids. Positive correlation of serum TSH with total cholesterol, LDL-cholesterol and triglycerides were seen in overt hypothyroid patients.
Conclusion: Deranged lipid profile is more marked in overt hypothyroidism and is characterized by increased total & LDL-cholesterol and triglycerides. Serum TSH level is positively correlated with the degree of dyslipidemia.
References
1. Tsimihodimos V, Bairaktari E, Tzallas C, Miltiadus G, Liberopoulos E, Elisaf M. Incidence of thyroid function abnormal-lities in patients attending an outpatient lipid clinic. Thyroid 1999; 9:365-8.
2. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994; 78:117-41.
3. Bakker O, Hudig F, Meijssen S, Wiersinga WM. Effects of T3 and amiodarone on promoter of human LDL receptor gene. Biochem Biophys Res Commun 1998; 249:517-21.
4. Shin DJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through SREBP-2. J Biol Chem 2003; 278:34114-8.
5. Walton KW, Scott PJ, Dykes PW, Davies JW. The significance of alterations in serum lipids in thyroid dysfunction. Clin Sci 1965; 29:217-38.
6. Thompson GR, Soutar AK, Spengel FA, Jadhav A, Gavigan SJ, Myant NB. Defects of receptor mediated LDL catabolism in hypercholesterolemia and hypothyroidism. Proc Natl Acad Sci USA 1981; 78:2591-5.
7. Abrams JJ, Grundy SM. Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res 1981; 22:323-38.
8. Lagrost L. Regulation of CETP activity: review of in vitro and in vivo studies. Biochim Biophys Acta 1994; 1215:209-36.
9. Kuusi T, Saarinen P, Nikkila EA. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma HDL-2. Atherosclerosis 1980; 36:589-93.
10. Santamarina FS, Navarro GH, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism and atherogenesis. Arterioscler Thromb Vasc Biol 2004; 24:1750-4.
11. Nikkila EA, Kekki M. Plasma triglyceride metabolism in thyroid disease.
J Clin Invest 1972; 51:2103-14.
12. Al-Tonsi A, Abdel AG, Saad M. Secondary dyslipidemia and deranged serum phosphate conc. in thyroid disorders. Exp Mol Pathol 2004; 76:182-7.
13. Teixeira PF, Reuters VS, Ferreira MM. Lipid profile in hypothyroidism and effects of LT4 in mild thyroid failure. Trans Res 2008; 151:224-31.
14. Pearce EN, Wilson PW, Yang Q, Vasan RS, Braverman LE. Thyroid function and lipid subparticle sizes in patients with short term hypothyroidism and a population based cohort. J Clin Endocrinol Metab 2008; 93:888-94.
15. Lam KS, Chan MK, Yeung RT. HDL-cholesterol, hepatic lipase and LPL activities in thyroid dysfunction - effect of treatment. QJ Med 1986; 59:513-21.
16. Lee WY, Suh JY, Rhee EJ, Park JS, Sung KC. Plasma CRP, apoA1, apoB and Lp(a) levels according to thyroid function. Arch Med Res 2004; 35:540-5.
17. Liberopoulos EN, Elisaf MS. Dyslipidemia in patients with thyroid disorders. Hormones 2002; 1(4):218-23.
18. Rizos CV, Elisaf MS and Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. The Open Cardiovascular Medicine Journal 2011; 5:76-84.
19. Hueston WJ, Pearson WS. Subclinical hypothyroidism and the risk of hypercholesterolemia. Am Fam Med 2004; 2:351-5.
20. Sheikh BA, Soomro AA, Soomro MA, Pirzado ZA. Lipid profile in primary hypothyroidism. Medical channel 2009; 15(4):15-8.
21. Efstathiadou Z, Bitsis S, Milionis HJ. Lipid profile in SH: is L-thyroxine substitution beneficial? Eur J Endocrinol 2001; 145:705-10.
22. Costantini F, Pierdomenico SD, Cesare DD. Effect of thyroid function on LDL oxidation. Arterioscler Thromb Vasc Biol 1998; 18:732-7.
23. Adrees M, Gibney J, Saeity N, Boran G. Effects of 18 months of L-T4
replacement in women with SH. J Clin Endocrinol 2009; 71:298-303.
24. Maugeri D, Santangelo A, Barbagallo P, Bonanno MR, Malaguarnera M, Rizza I, Speciale S. Thyroid hormones and lipid metabolism in a group of patients over seventy. Eur Rev Med Pharm Sci 1999; 3:211-6.
25. Prieur X, Huby T, Coste H. Thyroid Hormone Regulates the Hypotriglyceri-demic Gene APOA5. J Biol Chem 2005; 280(30):27533-43.
26. Abrams JJ, Grundy SM, Ginsberg H. Metabolism of plasma triglycerides in hypo and hyperthyroidism. J Lipid Res1981; 22:307-22.
27. Prakash A, Lal AK. Serum lipids in hypothyroidism: our experience. Indian J Clin Biochem 2006; 21(2):153-5.